ADMA Biologics, trading under NASDAQ:ADMA, is a prominent player in the medical sector. The company focuses on developing and manufacturing specialty plasma-derived products. A recent transaction on March 6, 2026, saw Steve Elms, a director at ADMA, purchase 7,000 shares at $15.39 each, increasing his total holdings to 2,045,730 shares. This transaction was reported on Form 4 and is accessible through the SEC filing.
ADMA Biologics showcases strong financial health, with impressive net margins of 28.8%, a return on equity of 37.52%, and a return on assets of 27.87%. These figures highlight the company's profitability and efficient use of resources. In comparison, Rezolute, another NASDAQ-listed medical company, struggles with negative returns, indicating financial challenges.
Institutional investors hold 75.7% of ADMA's shares, reflecting confidence in the company's long-term growth potential. Insider ownership stands at 3.7%, which is lower than Rezolute's 14.8%. This suggests that while insiders have a stake, institutional investors play a more significant role in ADMA's ownership structure.
ADMA's market valuation is evident in its price-to-earnings (P/E) ratio of 24.45, indicating how the market values its earnings. The price-to-sales ratio of 7.05 and enterprise value to sales ratio of 7.03 further emphasize investor willingness to pay for ADMA's sales. The company's enterprise value to operating cash flow ratio is high at 71.19, reflecting its valuation relative to cash flow.
ADMA maintains a low debt-to-equity ratio of 0.17, indicating a conservative approach to debt. Its strong current ratio of 6.71 demonstrates robust liquidity, ensuring the company can meet short-term liabilities. These financial metrics underscore ADMA's solid financial foundation and potential for sustained growth.
